MedTrace Logo

Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy

NCT00302523 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2012-02-03

No results posted yet for this study

Summary

The purpose of this study is:

* To explore the potential role of tacrolimus in the treatment of membranous nephropathy.
* To investigate the safety and tolerability of tacrolimus vs methylprednisolone plus cyclophosphamide.

Conditions

  • Idiopathic Membranous Nephropathy

Interventions

DRUG

Tacrolimus

FK506,0.1mg/kg/d

Sponsors & Collaborators

  • Nanjing University School of Medicine

    lead OTHER

Principal Investigators

  • Zhi-hong Liu, M.D. · Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-12-31
Completion
2009-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302523 on ClinicalTrials.gov